


PHARMACEUTICAL 2017



INTEGRATED BIOPHARMA INC Rank 83 of 313





PHARMACEUTICAL 2017



INTEGRATED BIOPHARMA INC Rank 83 of 313

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 884% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Other Expenses, reducing the Economic Capital Ratio by 654% points.

The company's Economic Capital Ratio, given in the ranking table, is -29%, being 388% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	12,070
Cost of Goods Sold	0
Intangible Assets	235
Liabilities, Current	11,824
Liabilities, Non-Current	5,306
Other Assets	213
Other Compr. Net Income	0
Other Expenses	36,941
Other Liabilities	5,282
Other Net Income	-925
Property and Equipment	1,567
Research and Development	0
Revenues	42,214
Selling, General and Administrative Expense	3,390

Output Variable	Value in 1000 USD
Assets	14,085
Liabilities	22,412
Expenses	40,331
Stockholders Equity	-8,327
Net Income	958
Comprehensive Net Income	958
Economic Capital Ratio	-29%